IDNA vs XBI

Key Takeaways

• IDNA offers concentrated thematic exposure to genomics, immunology, and bioengineering companies globally, while XBI provides broad, equal-weighted exposure to U.S. biotechnology firms.
• IDNA holds approximately 50 securities with top holdings often exceeding 4-5% each; XBI maintains around 150-160 holdings in a more diversified equal-weighted structure.
• IDNA carries a higher expense ratio of 0.47% compared to XBI’s 0.35%, reflecting its specialized thematic mandate versus XBI’s broader sector index approach.
• Both ETFs focus exclusively on the healthcare sector, but IDNA emphasizes innovation in genomics and immunology, whereas XBI captures the full spectrum of U.S. biotech companies regardless of market capitalization.
• IDNA’s global reach includes developed and emerging market issuers; XBI remains U.S.-centric and equal-weighted, reducing concentration risk in large-cap names.
• Structural differences position IDNA for investors seeking targeted innovation themes and XBI for those preferring diversified biotech sector participation with lower costs.

Introduction

Investors seeking healthcare sector exposure often compare thematic and broad biotechnology exchange-traded funds (ETFs). The iShares Genomics Immunology and Healthcare ETF (IDNA) and the SPDR S&P Biotech ETF (XBI) both target innovative healthcare companies yet employ distinct strategies. IDNA focuses on a narrow set of genomics, immunology, and bioengineering themes across global markets, while XBI delivers equal-weighted exposure to a wide array of U.S. biotechnology firms. These ETFs serve investors with overlapping yet differentiated goals within the same overarching sector, allowing comparison of concentration, cost, and geographic scope in a single article.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The iShares Genomics Immunology and Healthcare ETF (IDNA) is a passively managed thematic ETF that seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. The fund holds approximately 50 securities, with the top ten positions typically accounting for over 40% of assets. Representative top holdings include Moderna Inc., Bayer AG, and Exelixis Inc. Allocations concentrate in the healthcare sector at 100%. IDNA applies an expense ratio of 0.47% and follows a rules-based methodology that selects companies benefiting from long-term growth in genomics, immunology, and bioengineering. The ETF includes developed and emerging market issuers, providing geographic diversification within its narrow thematic mandate.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF (XBI) is a passively managed ETF designed to track the S&P Biotechnology Select Industry Index. The fund maintains approximately 150-160 holdings through an equal-weighted methodology that limits individual position sizes. Top holdings typically represent about 1.3-1.6% each, including names such as Moderna Inc., Apogee Therapeutics Inc., and Kymera Therapeutics Inc. The portfolio remains almost entirely within the healthcare sector. XBI features an expense ratio of 0.35% and rebalances periodically to maintain equal weights across U.S. biotechnology companies of varying market capitalizations.

Industry and Thematic Backdrop

The biotechnology and genomics segments operate within the broader healthcare sector, influenced by ongoing innovation in gene editing, immunotherapy, and personalized medicine. Capital flows into these areas respond to clinical trial outcomes, regulatory approvals from bodies such as the U.S. Food and Drug Administration, and macroeconomic factors including interest rate expectations that affect growth-oriented companies. Sector risks include high research and development costs, binary clinical results, and potential policy changes around drug pricing. Recent market cycles have highlighted rotation toward or away from smaller biotechnology firms depending on risk appetite and capital availability.

Performance and Positioning Comparison

In recent weeks and months, IDNA’s concentrated thematic approach has produced distinct volatility patterns tied to developments in genomics and immunology pipelines. XBI’s equal-weighted construction has delivered smoother relative performance during periods of sector rotation, as smaller-capitalization holdings contribute more evenly than in market-cap-weighted alternatives. Both ETFs respond to earnings cycles of key holdings and shifts in interest rate expectations, yet XBI’s broader diversification and lower expense ratio support more consistent positioning across biotech market cycles. Investors evaluating relative positioning note IDNA’s higher concentration risk alongside potential for outsized gains from successful innovation themes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional opportunities aligned with your investment criteria.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a modest preference to the SPDR S&P Biotech ETF (XBI). The ETF’s lower expense ratio, broader diversification across approximately 150 holdings, and equal-weighted methodology provide greater cost efficiency and reduced single-name risk compared with IDNA’s more concentrated thematic profile. While IDNA offers targeted exposure to genomics and immunology innovation, XBI’s positioning supports more consistent participation across biotech cycles with lower structural costs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations